CLINICAL TRIAL HIGHLIGHTS
TARGET:
Patients with relapsed primary
amyloidosis who have received
one line of prior therapy.
KEY INFORMATION:
Amyloidosis is a serious
complication of multiple
myeloma that affects up to 30%
of myeloma patients at some
point. This year, the MMRC has
added an amyloidosis trial to their
trial lineup for the first time ever!
This trial is studying how well
lenalidomide, dexamethasone,
and Empliciti with or without
Cytoxan work in treating patients
with primary amyloidosis that
has come back after a period
of improvement. These are
chemotherapy drugs that work
in different ways to stop the
growth of cancer cells by killing
them or stopping them from
dividing or s preading.
Empliciti is a monoclonal antibody
that may interfere with the
ability of cancer cells to grow
and spread. Giving lenalidomide,
dexamethasone, and Empliciti
with Cytoxan may work better in
treating patients with a relapse of
primary amyloidosis.
ACCEL E RATO R • W I N T E R 2017
CLINICAL TRIAL ID:
NCT02952573
Tafinlar and/or Mekinist in Patients
with Relapsed and/or Refractory
Multiple Myeloma and BRAF/NRAS/
KRAS Mutations FGFR3 Inhibitor JNJ-42756493 with
Dexamethasone for the Treatment
of Relapsed or Refractory Multiple
Myeloma
TARGET:
Patients with confirmed
mutations in the BRAF, NRAS,
or KRAS genes. TARGET:
Patients who have had at least
one prior line of treatment and
have a documented FGFR3 status.
KEY INFORMATION:
This pilot is evaluating two
drugs for the first time in
myeloma. Patients with multiple
myeloma whose tumors have a
mutation in the BRAF, NRAS, or
KRAS genes will be given one of
three treatments – dabrafenib
plus trametinib, dabrafenib alone,
or trametinib alone. KEY INFORMATION:
This study aims to determine
how effective investigational drug
JNJ-42756493 is when given
together with dexamethasone.
These mutations were first
documented in multiple
myeloma through research done
by the MMRF in our MMGI and
CoMMpass studies. Dabrafenib
and trametinib work to block the
BRAF, NRAS, and KRAS mutant
genes from contributing to the
spread of myeloma.
These drugs have already been
approved for treatment of other
BRAF/RAS mutant cancers, such
as melanoma, which suggests
that these agents may help to kill
mutant multiple myeloma cells.
This is the second MMRC trial
(the first was the MDM2 trial)
to offer a precision treatment
to patients based on their DNA
sequencing results.
Revlimid ® /Dexamethasone/
Empliciti™ for Patients with Relapsed
AL Amyloidosis
CLINICAL TRIAL ID:
NCT03091257
CLINICAL TRIAL ID:
NCT03252600
The study is looking at two groups
of patients: The first group have
tumors with a mutation in a
gene called Fibroblast Growth
Factor Receptor-3 (FGFR3),
which may be involved in the
growth of myeloma. The second
group of patients has tumors
containing a normal FGFR3
gene. JNJ-42756493 has shown
effectiveness against tumors with
mutant FGFR3 and may boost the
effectiveness of dexamethasone
for these patients.
The existence of FGFR3 mutations
in myeloma was confirmed in our
CoMMpass Study. This is the third
precision medicine treatment
that has advanced into an MMRC
clinical trial for myeloma patients
as a result of genomic data
generated by the MMRF.
9